Join the Diabetes, Type 2 group to help and get support from people like you.
Diabetes, Type 2 News (Page 20)
Related terms: Noninsulin-dependent Diabetes, Type 2 Diabetes, Diabetes, Type 2
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 – For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists (GLP-1 RA) and...
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 – For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists (GLP-1 RA) and...
Diabetes Tied to Higher Prevalence of Overactive Bladder
TUESDAY, June 4, 2024 – Markers of diabetes are positively associated with overactive bladder (OAB), according to a study published online April 28 in Frontiers in Endocrinology. Qingliu He, from ...
GLP-1 Weight Loss Meds Might Keep Your Pancreas Healthy
MONDAY, June 3, 2024 – Ozempic and Wegovy might help lower the risk of pancreatitis in patients with obesity and type 2 diabetes, a new study says. Up to now, doctors have been cautious about...
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 – For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from cardiovascular causes,...
Demographic, Clinical, Financial Factors Tied to GLP-1 Agonist Discontinuation
WEDNESDAY, May 29, 2024 – Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor agonist discontinuation, according to a research...
Ozempic Lowers Odds for Death, Illness in People With Kidney Disease and Type 2 Diabetes
FRIDAY, May 24, 2024 – Ozempic provides a wide variety of health benefits for people with kidney disease and type 2 diabetes, a major clinical trial has found. The drug significantly reduces the...
Costs, Side Effects Drive Folks to Quit New Weight-Loss Meds
THURSDAY, May 23, 2024 – Three months after starting one of the new GLP-1 weight-loss drugs, more than a quarter of patients have already quit the medications, and by a year from first use more than...
Use of GLP-1 Meds Have Risen 7-Fold Among Young Americans
WEDNESDAY, May 22, 2024 – The number of American teens and young adults who've been prescribed one of the new GLP-1 weight-loss drugs soared nearly seven-fold between 2020 and 2023, a new report...
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 – For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research letter published...
Men Are More Debilitated by Diabetes Than Women
FRIDAY, May 17, 2024 – Men are more vulnerable than women to the debilitating effects of diabetes, a new long-term study finds. Overall rates of diabetes are similar between men and women, according...
Men Face More Diabetes Complications Than Women
FRIDAY, May 17, 2024 – Men with diabetes have a greater risk for complications than women, irrespective of diabetes duration, according to a study published online May 16 in the Journal of ...
Four in 10 Adults With Diabetes Report Taking a GLP-1 Receptor Agonist
TUESDAY, May 14, 2024 – One in eight adults (12 percent) say they have ever taken a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and 6 percent say they are currently using one, according to...
AI-Informed Health App Aids Diabetes Outcomes
WEDNSDAY, May 15, 2024 – Use of an artificial intelligence (AI)-informed health app aids diabetes outcomes and cuts atherosclerotic cardiovascular disease (ASCVD) risk, according to a study...
Fat-Enlarged Axillary Nodes on Mammogram May Indicate Higher CVD Risk
TUESDAY, May 14, 2024 – Fat-enlarged axillary nodes on screening mammograms can predict the risk for cardiovascular disease (CVD), according to a study presented at the annual meeting of the...
Further information
Related condition support groups
Related drug support groups
metformin, Ozempic, Victoza, Mounjaro, Lantus, semaglutide, Trulicity, glipizide, Rybelsus, view more... Farxiga, Jardiance, Lantus Solostar, Humalog, Novolog, liraglutide, Janumet, insulin glargine, tirzepatide, Januvia, insulin lispro, Bydureon, Tresiba, Levemir, dulaglutide, Glucophage, Invokana, insulin degludec, Humulin N